The presence of pre-existing immunity is important, as high pre-existing immunity towards the native HER-2 peptide, AE36, in patients with PCa has been shown to correlate with longer PFS following vaccination with a HER-2/neu hybrid peptide vaccine [22]. The gene discussed is ERBB2; the disease is posterior cortical atrophy.